Vera Therapeutics (VERA) to Release Earnings on Tuesday

Key Points

• Q1 2026 results due before the market opens Tuesday, May 5, with analysts expecting EPS of ($1.3284) and revenue of about $0.426M; the earnings conference call is scheduled for Wednesday, May 6 at 12:30 PM ET.
• Analysts hold a consensus rating of Moderate Buy (10 Buys, 1 Hold, 1 Sell) with an average price target of $81.45, following recent upgrades and higher price targets from Wolfe Research and HC Wainwright.
• Vera recently missed prior-quarter EPS (reported ($1.39)), analysts expect roughly -$5 EPS for the current fiscal year and - $3 next year, and insiders sold 56,441 shares (~$2.42M) over the last three months while owning 15.9% of the stock.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) is expected to post its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Vera Therapeutics to post earnings of ($1.3284) per share and revenue of $0.4260 million for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 12:30 PM ET.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.34) by ($0.05). During the same quarter in the prior year, the business earned ($0.72) earnings per share. On average, analysts expect Vera Therapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Vera Therapeutics Stock Down 1.1%

Shares of NASDAQ:VERA opened at $37.28 on Tuesday. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of -8.00 and a beta of 1.17. The company has a debt-to-equity ratio of 0.12, a current ratio of 13.64 and a quick ratio of 13.64. The business's 50-day moving average is $40.76 and its 200-day moving average is $40.13. Vera Therapeutics has a 1 year low of $18.76 and a 1 year high of $56.05.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Wolfe Research raised Vera Therapeutics from a "peer perform" rating to an "outperform" rating and set a $88.00 price objective on the stock in a research note on Wednesday, March 11th. HC Wainwright boosted their price objective on Vera Therapeutics from $90.00 to $110.00 and gave the company a "buy" rating in a research note on Monday, March 2nd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $81.45.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, CFO Sean Grant sold 4,949 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $207,759.02. Following the completion of the sale, the chief financial officer owned 114,181 shares in the company, valued at approximately $4,793,318.38. The trade was a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider William D. Turner sold 2,187 shares of the company's stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $91,810.26. Following the transaction, the insider owned 45,313 shares in the company, valued at approximately $1,902,239.74. The trade was a 4.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 56,441 shares of company stock valued at $2,416,902 over the last three months. 15.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in VERA. Los Angeles Capital Management LLC acquired a new position in shares of Vera Therapeutics during the fourth quarter valued at about $46,000. Quantbot Technologies LP acquired a new position in shares of Vera Therapeutics during the second quarter valued at about $51,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Vera Therapeutics during the fourth quarter valued at about $71,000. Tower Research Capital LLC TRC raised its stake in shares of Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company's stock worth $99,000 after purchasing an additional 2,757 shares during the last quarter. Finally, Sandia Investment Management LP purchased a new stake in shares of Vera Therapeutics in the fourth quarter worth approximately $127,000. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.